rabusertib
Term · Oncology and biomedicine · MLC-T-ONC-016337
An inhibitor of the cell cycle checkpoint kinase 2 (chk2) with potential chemopotentiating activity. Rabusertib binds to and inhibits the activity of chk2, which may prevent the repair of DNA caused by DNA-damaging agents, thus potentiating the antitumor efficacies of various chemotherapeutic agents. Chk2, an ATP-dependent serine-threonine kinase, is a key component in the DNA replication-monitoring checkpoint system and is activated by double-stranded breaks (DSBs); activated chk2 is overexpressed by a variety of cancer cell types.
| Identifier | MLC-T-ONC-016337 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | checkpoint kinase 2 inhibitor LY2603618; CHK2 inhibitor LY2603618 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-016337",
"term": "rabusertib",
"field": "Oncology and biomedicine",
"definition": "An inhibitor of the cell cycle checkpoint kinase 2 (chk2) with potential chemopotentiating activity. Rabusertib binds to and inhibits the activity of chk2, which may prevent the repair of DNA caused by DNA-damaging agents, thus potentiating the antitumor efficacies of various chemotherapeutic agents. Chk2, an ATP-dependent serine-threonine kinase, is a key component in the DNA replication-monitoring checkpoint system and is activated by double-stranded breaks (DSBs); activated chk2 is overexpressed by a variety of cancer cell types.",
"synonyms": [
"checkpoint kinase 2 inhibitor LY2603618",
"CHK2 inhibitor LY2603618"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/rabusertib/"
}
Record 13,962 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.